<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">surgonco</journal-id><journal-title-group><journal-title xml:lang="ru">Креативная хирургия и онкология</journal-title><trans-title-group xml:lang="en"><trans-title>Creative surgery and oncology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2076-3093</issn><issn pub-type="epub">2307-0501</issn><publisher><publisher-name>Башкирский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24060/2076-3093-2025-15-2-19-27</article-id><article-id custom-type="elpub" pub-id-type="custom">surgonco-1084</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Анализ и функциональная значимость белка TRAP1 при глиобластоме</article-title><trans-title-group xml:lang="en"><trans-title>Analysis and Functional Significance of TRAP1 in Glioblastoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4965-0835</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гареев</surname><given-names>И. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Gareev</surname><given-names>I. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гареев Ильгиз Фанилевич — к.м.н., старший научный сотрудник</p><p>Республика Башкортостан, Уфа; Москва </p></bio><bio xml:lang="en"><p>Ilgiz F. Gareev — Cand. Sci. (Med.), Senior Researcher</p><p>Ufa; Moscow </p></bio><email xlink:type="simple">ilgiz_gareev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6149-5460</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бейлерли</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Beylerli</surname><given-names>O.A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бейлерли Озал Арзуман оглы — к.м.н., старший научный сотрудник</p><p>Республика Башкортостан, Уфа; Москва</p></bio><bio xml:lang="en"><p>Ozal A. Beylerli — Cand. Sci. (Med.), Senior Researcher</p><p>Ufa; Moscow </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-4036-519X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хонгли</surname><given-names>Жанг</given-names></name><name name-style="western" xml:lang="en"><surname>Hongli</surname><given-names>Zhang</given-names></name></name-alternatives><bio xml:lang="ru"><p>Жанг Хонгли — младший научный сотрудник, отделение нейрохирургии</p><p>Харбин </p></bio><bio xml:lang="en"><p>Hongli Zhang — Junior Research Assistant, Neurosurgery Unit</p><p>Harbin </p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7418-0222</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцев</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Roumiantsev</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Румянцев Сергей Александрович — д.м.н., профессор, член-корр. РАН</p><p>Москва</p></bio><bio xml:lang="en"><p>Sergey A. Roumiantsev — Dr. Sci. (Med.), Prof., Corresponding Member of the Russian Academy of Sciences</p><p>Moscow</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Центральная научно-исследовательская лаборатория, Башкирский государственный медицинский университет ; Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Research Laboratory, Bashkir State Medical University ; Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Центральная научно-исследовательская лаборатория, Башкирский государственный медицинский университет ; Российский университет дружбы народов имени Патриса Лумумбы</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Central Research Laboratory, Bashkir State Medical University ; RUDN University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Первый аффилированный госпиталь Харбинского медицинского университета ; Институт нейронаук провинции Хэйлунцзян</institution><country>Китай</country></aff><aff xml:lang="en"><institution>First Affiliated Hospital of Harbin Medical University ;  Heilongjiang Province Neuroscience Institute</institution><country>China</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова ; Национальный медицинский исследовательский центр эндокринологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pirogov Russian National Research Medical University ; National Medical Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>01</day><month>07</month><year>2025</year></pub-date><volume>15</volume><issue>2</issue><fpage>115</fpage><lpage>123</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гареев И.Ф., Бейлерли О., Хонгли Ж., Румянцев С.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Гареев И.Ф., Бейлерли О., Хонгли Ж., Румянцев С.А.</copyright-holder><copyright-holder xml:lang="en">Gareev I.F., Beylerli O., Hongli Z., Roumiantsev S.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surgonco.ru/jour/article/view/1084">https://www.surgonco.ru/jour/article/view/1084</self-uri><abstract><p>Введение. Глиобластома характеризуется высоким уровнем агрессивности и сложными механизмами формирования лекарственной резистентности. Белок 1, ассоциированный с рецептором TNF (TRAP1), задействован в регуляции метаболических процессов и устойчивости опухолевых клеток к апоптозу, однако его роль в глиобластоме остается недостаточно изученной. Материалы и методы. Использовали клеточные линии глиомы T98G и астроциты головного мозга человека (HBA) в качестве контроля. Подавление экспрессии TRAP1 осуществляли методом лентивирусной трансдукции короткой шпилечной РНК (кшРНК). Экзосомы выделяли ультрацентрифугированием из культуральной среды и подтверждали их идентификацию по типичным маркерам (TSG101, CD63 и ALIX). Уровень экспрессии TRAP1 на уровне белка и ключевых гликолитических ферментов анализировали методом вестерн-блот анализа. Оценку жизнеспособности опухолевых клеток проводили с помощью МТТ-теста, уровень апоптоза — с помощью аннексина V-FITC/PI и продукцию АТФ — методом биолюминесцентного анализа. Результаты и обсуждение. Показано, что в клетках T98G TRAP1 сверхэкспрессирован, в том числе и в экзосомах, тогда как в HBA уровень TRAP1 был умеренным или низким. Подавление TRAP1 у T98G приводило к снижению экспрессии гликолитических ферментов, росту уровня апоптоза и уменьшению жизнеспособности опухолевых клеток. Повышенная экспрессия TRAP1 усиливала метаболическое перепрограммирование опухолевых клеток в сторону аэробного гликолиза и снижала синтез АТФ. Экзосомальный TRAP1, вероятно, участвует в межклеточной коммуникации, способствуя адаптации опухоли к стрессовым условиям и формированию проопухолевого микроокружения. Заключение. Результаты исследования подтверждают важность TRAP1 в регуляции метаболического статуса глиобластомы и поддержании ее агрессивного фенотипа. Таргетное подавление TRAP1 может рассматриваться как перспективная стратегия терапии глиобластомы, направленная на снижение жизнеспособности опухолевых клеток и ограничение их метаболической гибкости.</p></abstract><trans-abstract xml:lang="en"><p>Introduction. Glioblastoma exhibits high aggressiveness and complex mechanisms of therapy resistance. Tumor necrosis factor receptor-associated protein 1 (TRAP1) participates in metabolic regulation and tumor cell resistance to apoptosis; however, its role in glioblastoma remains understudied. Materials and methods. Glioma cell lines T98G and human brain astrocytes (HBA) were used as controls. TRAP1 expression was suppressed via the lentiviral transduction method using short hairpin RNA (shRNA). Exosomes were isolated from culture medium by ultracentrifugation and subsequently identified by typical markers (TSG101, CD63, and ALIX). The protein-level expression of TRAP1 and key glycolytic enzymes was analyzed by western blot analysis. Cell viability was assessed using the MTT assay, while apoptosis levels were measured using Annexin V-FITC/PI staining. In addition, ATP production was analyzed using bioluminescent methods. Results and discussion. TRAP1 was overexpressed in T98G cells, including in exosomes, while HBA exhibited moderate to low TRAP1 levels. The suppression of TRAP1 in T98G cells resulted in a decrease in glycolytic enzyme expression, an increase in apoptosis, and a decrease in cell viability. TRAP1 overexpression facilitated metabolic reprogramming toward aerobic glycolysis, along with reducing ATP synthesis. Exosomal TRAP1 likely participates in intercellular communication, promoting tumor adaptation to stress and the formation of a pro-tumor microenvironment. Conclusion. These findings support the pivotal role of TRAP1 in regulating metabolic status and maintaining aggressive phenotypes in glioblastoma. The targeted inhibition of TRAP1 may become a promising therapeutic strategy for glioblastoma, aimed at reducing tumor cell viability and limiting metabolic flexibility.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>глиобластома</kwd><kwd>TRAP1</kwd><kwd>метаболическое перепрограммирование</kwd><kwd>кшРНК</kwd><kwd>экзосомы</kwd><kwd>гликолиз</kwd><kwd>апоптоз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>glioblastoma</kwd><kwd>TRAP1</kwd><kwd>metabolic reprogramming</kwd><kwd>shRNA</kwd><kwd>exosomes</kwd><kwd>glycolysis</kwd><kwd>apoptosis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bush N.A., Chang S.M., Berger M.S. Current and future strategies for treatment of glioma. Neurosurg Rev. 2017;40(1):1–14. DOI: 10.1007/s10143-016-0709-8</mixed-citation><mixed-citation xml:lang="en">Bush N.A., Chang S.M., Berger M.S. Current and future strategies for treatment of glioma. Neurosurg Rev. 2017;40(1):1–14. DOI: 10.1007/s10143-016-0709-8</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Lim M., Xia Y., Bettegowda C., Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–42. DOI: 10.1038/s41571-018-0003-5</mixed-citation><mixed-citation xml:lang="en">Lim M., Xia Y., Bettegowda C., Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–42. DOI: 10.1038/s41571-018-0003-5</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. DOI: 10.1016/j.cell.2013.09.034</mixed-citation><mixed-citation xml:lang="en">Brennan C.W., Verhaak R.G., McKenna A., Campos B., Noushmehr H., Salama S.R., et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. DOI: 10.1016/j.cell.2013.09.034</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Tan A.C., Ashley D.M., López G.Y., Malinzak M., Friedman H.S., Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312. DOI: 10.3322/caac.21613</mixed-citation><mixed-citation xml:lang="en">Tan A.C., Ashley D.M., López G.Y., Malinzak M., Friedman H.S., Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312. DOI: 10.3322/caac.21613</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Yilmaz S., Cizmecioglu O. PI3K signaling at the crossroads of lipid metabolism and cancer. Adv Exp Med Biol. 2025;1479:139–64. DOI: 10.1007/5584_2024_832</mixed-citation><mixed-citation xml:lang="en">Yilmaz S., Cizmecioglu O. PI3K signaling at the crossroads of lipid metabolism and cancer. Adv Exp Med Biol. 2025;1479:139–64. DOI: 10.1007/5584_2024_832</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Chinopoulos C. Mitochondrial consumption of cytosolic ATP: not so fast. FEBS Lett. 2011;585(9):1255–9. DOI: 10.1016/j.febslet.2011.04.004</mixed-citation><mixed-citation xml:lang="en">Chinopoulos C. Mitochondrial consumption of cytosolic ATP: not so fast. FEBS Lett. 2011;585(9):1255–9. DOI: 10.1016/j.febslet.2011.04.004</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wang S.F., Tseng L.M., Lee H.C. Role of mitochondrial alterations in human cancer progression and cancer immunity. J Biomed Sci. 2023;30(1):61. DOI: 10.1186/s12929-023-00956-w</mixed-citation><mixed-citation xml:lang="en">Wang S.F., Tseng L.M., Lee H.C. Role of mitochondrial alterations in human cancer progression and cancer immunity. J Biomed Sci. 2023;30(1):61. DOI: 10.1186/s12929-023-00956-w</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010;430(2):199–205. DOI: 10.1042/BJ20100814</mixed-citation><mixed-citation xml:lang="en">Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010;430(2):199–205. DOI: 10.1042/BJ20100814</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hoter A., El-Sabban M.E., Naim H.Y. The HSP90 Family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018;19(9):2560. DOI: 10.3390/ijms19092560</mixed-citation><mixed-citation xml:lang="en">Hoter A., El-Sabban M.E., Naim H.Y. The HSP90 Family: structure, regulation, function, and implications in health and disease. Int J Mol Sci. 2018;19(9):2560. DOI: 10.3390/ijms19092560</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ramkumar B., Dharaskar S.P., Mounika G., Paithankar K., Sreedhar A.S. Mitochondrial chaperone, TRAP1 as a potential pharmacological target to combat cancer metabolism. Mitochondrion. 2020;50:42– 50. DOI: 10.1016/j.mito.2019.09.011.</mixed-citation><mixed-citation xml:lang="en">Ramkumar B., Dharaskar S.P., Mounika G., Paithankar K., Sreedhar A.S. Mitochondrial chaperone, TRAP1 as a potential pharmacological target to combat cancer metabolism. Mitochondrion. 2020;50:42– 50. DOI: 10.1016/j.mito.2019.09.011.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Chae Y.C., Angelin A., Lisanti S., Kossenkov A.V., Speicher K.D., Wang H., et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2013;4:2139. DOI: 10.1038/ncomms3139</mixed-citation><mixed-citation xml:lang="en">Chae Y.C., Angelin A., Lisanti S., Kossenkov A.V., Speicher K.D., Wang H., et al. Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat Commun. 2013;4:2139. DOI: 10.1038/ncomms3139</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Masgras I., Sanchez-Martin C., Colombo G., Rasola A. The Chaperone TRAP1 as a modulator of the mitochondrial adaptations in cancer cells. Front Oncol. 2017;7:58. DOI: 10.3389/fonc.2017.00058</mixed-citation><mixed-citation xml:lang="en">Masgras I., Sanchez-Martin C., Colombo G., Rasola A. The Chaperone TRAP1 as a modulator of the mitochondrial adaptations in cancer cells. Front Oncol. 2017;7:58. DOI: 10.3389/fonc.2017.00058</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Matassa D.S., Agliarulo I., Avolio R., Landriscina M., Esposito F. TRAP1 Regulation of cancer metabolism: dual role as oncogene or tumor suppressor. Genes (Basel). 2018;9(4):195 DOI: 10.3390/genes9040195</mixed-citation><mixed-citation xml:lang="en">Matassa D.S., Agliarulo I., Avolio R., Landriscina M., Esposito F. TRAP1 Regulation of cancer metabolism: dual role as oncogene or tumor suppressor. Genes (Basel). 2018;9(4):195 DOI: 10.3390/genes9040195</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Wengert L.A., Backe S.J., Bourboulia D., Mollapour M., Woodford M.R. TRAP1 chaperones the metabolic switch in cancer. Biomolecules. 2022;12(6):786. DOI: 10.3390/biom12060786</mixed-citation><mixed-citation xml:lang="en">Wengert L.A., Backe S.J., Bourboulia D., Mollapour M., Woodford M.R. TRAP1 chaperones the metabolic switch in cancer. Biomolecules. 2022;12(6):786. DOI: 10.3390/biom12060786</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kalluri R., McAndrews K.M. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610–26. DOI: 10.1016/j.cell.2023.03.010</mixed-citation><mixed-citation xml:lang="en">Kalluri R., McAndrews K.M. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610–26. DOI: 10.1016/j.cell.2023.03.010</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Whiteside T.L. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin Immunol. 2018;35:69–79. DOI: 10.1016/j.smim.2017.12.003</mixed-citation><mixed-citation xml:lang="en">Whiteside T.L. Exosome and mesenchymal stem cell cross-talk in the tumor microenvironment. Semin Immunol. 2018;35:69–79. DOI: 10.1016/j.smim.2017.12.003</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Akers J.C., Gonda D., Kim R., Carter B.S., Chen C.C. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113(1):1–11. DOI: 10.1007/s11060-013-1084-8</mixed-citation><mixed-citation xml:lang="en">Akers J.C., Gonda D., Kim R., Carter B.S., Chen C.C. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113(1):1–11. DOI: 10.1007/s11060-013-1084-8</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kalluri R., LeBleu V.S. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. DOI: 10.1126/science.aau6977</mixed-citation><mixed-citation xml:lang="en">Kalluri R., LeBleu V.S. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. DOI: 10.1126/science.aau6977</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fridman E.S., Ginini L., Gil Z. The role of extracellular vesicles in metabolic reprogramming of the tumor microenvironment. Cells. 2022;11(9):1433. DOI: 10.3390/cells11091433</mixed-citation><mixed-citation xml:lang="en">Fridman E.S., Ginini L., Gil Z. The role of extracellular vesicles in metabolic reprogramming of the tumor microenvironment. Cells. 2022;11(9):1433. DOI: 10.3390/cells11091433</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Yang E., Wang X., Gong Z., Yu M., Wu H., Zhang D. Exosomemediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020;5(1):242. DOI: 10.1038/s41392-020-00359-5</mixed-citation><mixed-citation xml:lang="en">Yang E., Wang X., Gong Z., Yu M., Wu H., Zhang D. Exosomemediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther. 2020;5(1):242. DOI: 10.1038/s41392-020-00359-5</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">van Ommeren R., Staudt M.D., Xu H., Hebb M.O. Advances in HSP27 and HSP90-targeting strategies for glioblastoma. J Neurooncol. 2016;127(2):209–19. DOI: 10.1007/s11060-016-2070-8</mixed-citation><mixed-citation xml:lang="en">van Ommeren R., Staudt M.D., Xu H., Hebb M.O. Advances in HSP27 and HSP90-targeting strategies for glioblastoma. J Neurooncol. 2016;127(2):209–19. DOI: 10.1007/s11060-016-2070-8</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Li X., Jing Z., Li X., Liu L., Xiao X., Zhong Y., et al. The role of exosomes in cancer-related programmed cell death. Immunol Rev. 2024;321(1):169–80. DOI: 10.1111/imr.13286</mixed-citation><mixed-citation xml:lang="en">Li X., Jing Z., Li X., Liu L., Xiao X., Zhong Y., et al. The role of exosomes in cancer-related programmed cell death. Immunol Rev. 2024;321(1):169–80. DOI: 10.1111/imr.13286</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Matassa D.S., Amoroso M.R., Lu H., Avolio R., Arzeni D., Procaccini C., et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23(9):1542–54. DOI: 10.1038/cdd.2016.39</mixed-citation><mixed-citation xml:lang="en">Matassa D.S., Amoroso M.R., Lu H., Avolio R., Arzeni D., Procaccini C., et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23(9):1542–54. DOI: 10.1038/cdd.2016.39</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chen S., Cao G., Wu W., Lu Y., He X., Yang L., et al. Mining novel cell glycolysis related gene markers that can predict the survival of colon adenocarcinoma patients. Biosci Rep. 2020;40(8):BSR20201427. DOI: 10.1042/BSR20201427</mixed-citation><mixed-citation xml:lang="en">Chen S., Cao G., Wu W., Lu Y., He X., Yang L., et al. Mining novel cell glycolysis related gene markers that can predict the survival of colon adenocarcinoma patients. Biosci Rep. 2020;40(8):BSR20201427. DOI: 10.1042/BSR20201427</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Jhaveri K., Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol. 2012;65:471–517. DOI: 10.1016/B978-0-12-397927-8.00015-4</mixed-citation><mixed-citation xml:lang="en">Jhaveri K., Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol. 2012;65:471–517. DOI: 10.1016/B978-0-12-397927-8.00015-4</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Karami Fath M., Azami J., Masoudi A., Mosaddeghi Heris R., Rahmani E., Alavi F., et al. Exosome-based strategies for diagnosis and therapy of glioma cancer. Cancer Cell Int. 2022;22(1):262. DOI: 10.1186/s12935-022-02642-7</mixed-citation><mixed-citation xml:lang="en">Karami Fath M., Azami J., Masoudi A., Mosaddeghi Heris R., Rahmani E., Alavi F., et al. Exosome-based strategies for diagnosis and therapy of glioma cancer. Cancer Cell Int. 2022;22(1):262. DOI: 10.1186/s12935-022-02642-7</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Porporato P.E., Filigheddu N., Pedro J.M.B., Kroemer G., Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–80. DOI: 10.1038/cr.2017.155</mixed-citation><mixed-citation xml:lang="en">Porporato P.E., Filigheddu N., Pedro J.M.B., Kroemer G., Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–80. DOI: 10.1038/cr.2017.155</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Indira Chandran V., Gopala S., Venkat E.H., Kjolby M., Nejsum P. Extracellular vesicles in glioblastoma: a challenge and an opportunity. NPJ Precis Oncol. 2024;8(1):103. DOI: 10.1038/s41698-024-00600-2</mixed-citation><mixed-citation xml:lang="en">Indira Chandran V., Gopala S., Venkat E.H., Kjolby M., Nejsum P. Extracellular vesicles in glioblastoma: a challenge and an opportunity. NPJ Precis Oncol. 2024;8(1):103. DOI: 10.1038/s41698-024-00600-2</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
